Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia



Status:Archived
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:July 2010
End Date:December 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase


Purpose of the study is to determine if Cimzia is safe and effective in subjects who have
received previous treatment with a TNF-alpha inhibitor other than Cimzia.



We found this trial at
10
sites
Clinical Trial Facility
Milwaukee, Wisconsin
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Clinical Trial Facility
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Clinical Trial Facility
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clinical Trial Facility
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Clinical Trial Facility
Morgantown, West Virginia
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Clinical Trial Facility
Omaha, Nebraska
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Clinical Trial Facility
Peoria, Arizona
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
Clinical Trial Facility
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Trial Facility
St Louis, Missouri
?
mi
from
St Louis, MO
Click here to add this to my saved trials
Clinical Trial Facility
West Orange, New Jersey
?
mi
from
West Orange, NJ
Click here to add this to my saved trials